How Fast Can We Go: Abbreviated Prostate MR Protocols
- PDF / 402,432 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 66 Downloads / 217 Views
NEW IMAGING TECHNIQUES (S RAIS-BAHRAMI AND K PORTER, SECTION EDITORS)
How Fast Can We Go: Abbreviated Prostate MR Protocols Neha Udayakumar 1 & Kristin K. Porter 2 Accepted: 15 October 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose of Review Multiparametric MRI (mpMRI), composed of T2WI, DWI, and DCE sequences, is effective in identifying prostate cancer (PCa), but length and cost preclude its application as a PCa screening tool. Here we review abbreviated MRI protocols that shorten or omit conventional mpMRI components to reduce scan time and expense without forgoing diagnostic accuracy. Recent Findings The DCE sequence, which plays a limited diagnostic role in PI-RADS, is eliminated in variations of the biparametric MRI (bpMRI). T2WI, the lengthiest sequence, is truncated by only acquiring the axial plane or utilizing 3D acquisition with subsequent 2D reconstruction. DW-EPISMS further accelerates DWI acquisition. The fastest protocol described to date consists of just DW-EPISMS and axial-only 2D T2WI and runs less than 5 min. Summary Abbreviated protocols can mitigate scan expense and increase scan access, allowing prostate MRI to become an efficient PCa screening tool. Keywords Fast MRI . Biparametric prostate MRI . Access . Cost . Fiscal responsibility
Introduction Prostate cancer (PCa) has the highest incidence of all noncutaneous cancers in American men and is the second most common cause of cancer death in this population [1]. The 2018 US Preventative Services Task Force (USPSTF) guidelines state that routine screening for PCa using prostatespecific antigen (PSA) can be associated with a high falsepositive rate and over-diagnosis, leading to unnecessary biopsies and other interventions without clear mortality benefits [2]. There is a dire need for an effective screening tool that can identify clinically significant prostate cancer (csPCa) cases to allow for timely treatment intervention. This screening tool should also limit the over-diagnosis of non-csPCa, thus avoiding adverse effects associated with unnecessary
This article is part of the Topical Collection on New Imaging Techniques * Kristin K. Porter [email protected] 1
University of Alabama at Birmingham School of Medicine, 1720 2nd Ave S, Birmingham, AL 35249, USA
2
Department of Radiology, University of Alabama at Birmingham, 619 19th Street S, JT N374, Birmingham, AL 35249, USA
biopsies and treatment, such as erectile dysfunction and urinary incontinence. Magnetic resonance imaging (MRI) serves multiple roles in the detection and management of PCa and shows great promise as a non-invasive screening tool [3,4]. The MRI protocol recommended by the most recent Prostate Imaging Reporting and Data System (PI-RADS), version 2.1 released in 2019, includes T2-weighted imaging (T2WI), diffusionweighted imaging (DWI), and dynamic contrast-enhanced ( D C E ) i m a g i n g s e q u e n c e s a n d is r e f e r r e d t o a s multiparametric MRI (mpMRI) [5]. It allows a lesion to be scored from 1 to 5 with PI-RA
Data Loading...
